Safety of therapeutic monoclonal antibodies

Current Drug Safety

Volumn 5, Issue 4, 2010, Pages 275-286

  Niebecker, Ronald ^a   Kloft, Charlotte ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Adverse drug reaction (ADR); Antibody fusion proteins; Drug safety; Human anti drug antibodies (HADAs); Immunogenicity; Monoclonal antibodies

Indexed keywords

ABATACEPT; ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ANTIBODY; ANTIBODY CONJUGATE; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; HUMAN ANTIDRUG ANTIBODY; HYBRID PROTEIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; ORTHOCLONE OKT 3; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ABSCESS; ADVERSE DRUG REACTION; ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; BLOOD DISEASE; BLOOD TOXICITY; BREAST CANCER; CARCINOGENICITY; CARDIOTOXICITY; CELLULITIS; CHRONIC DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEEP VEIN THROMBOSIS; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIGESTIVE SYSTEM PERFORATION; DIVERTICULOSIS; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EPSTEIN BARR VIRUS INFECTION; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGICAL TOXICITY; HEPATITIS B; HERPES ZOSTER; HERPETIC STOMATITIS; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; HYPERSENSTIVITY; HYPERTENSION; HYPOCALCEMIA; HYPOMAGNESEMIA; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LIPID LIVER LEVEL; LUNG CANCER; LUNG EMBOLISM; LUNG HEMORRHAGE; LUPUS LIKE SYNDROME; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PALLIATIVE THERAPY; PATIENT MONITORING; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREMEDICATION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT INDICATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VIREMIA; VIRUS INFECTION; VIRUS REACTIVATION; WOUND HEALING IMPAIRMENT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; NEOPLASMS;

EID: 77958503615     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610792246055     Document Type: Article

References (57)

1. Duebel S. Recombinant therapeutic antibodies. Appl Microbiol Biotechnol 2007; 74: 723-729.
2. Maggon K. Monoclonal antibody gold rush. Curr Med Chem 2007; 14: 1978-1987.
3. Duebel S. In: Duebel S Ed, Handbook of Therapeutic Antibodies. Weinheim, WILEY-VCH. 2007; 3-16.
4. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9: 423-430.
5. Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 2008; 4: 1537-1549.
6. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
7. Muller PY, Brennan FR. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 2009; 85: 247-258.
8. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. London: EMA2007. Doc. Ref.EMA/CHMP/SWP/28367/07.
9. International Drug Monitoring: The Role of the Hospital. Report of a WHO Meeting. Geneve: World Health Organization 1969.
10. Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances. Geneva: World Health Organization 1997.
11. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36: 3-10.
12. Gilliland LK, Walsh LA, Frewin MR, et al. Elimination of the immunogenicity of therapeutic antibodies. J Immunol 1999; 162: 3663-3671.
13. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-661.
14. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of antiantibody measurement. Curr Opin Immunol 2008; 20: 431-435.
15. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-926.
16. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005; 72: 250-256.
17. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289: 1-16.
18. Lofgren JA, Dhandapani S, Pennucci JJ, et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 2007; 178: 7467-7472.
19. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009; 21: 211-215.
20. EPARs for authorised medicinal products for human use. London: European Medicines Agency; [updated 7 July 2008; cited 2009]; Available from: http://www.EMA.europa.eu/htms/human/epar/eparintro.htm.
21. Guideline on Risk Management Systems For Medicinal Products For Human Use. London: European Medicines Agency 2005. Doc. Ref. EMA/CHMP/96268/2005.
22. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007; 12: 540-547.
23. Fischer P, Uttenreuther-Fischer MM. In: Duebel S Ed, Handbook of Therapeutic Antibodies. Weinheim, WILEY-VCH. 2007; 573-590.
24. Fehr T, Bachmann MF, Bucher E, et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 1997; 185: 1785-1792.
25. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24: 1720-1740; discussion 19.
26. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925.
27. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391-1403.
28. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009; 88: 121-132.
29. Christian BA, Lin TS. Antibody therapy for chronic lymphocytic leukemia. Semin Hematol 2008; 45: 95-103.
30. Khalili K, White MK. Human demyelinating disease and the polyomavirus JCV. Mult Scler 2006; 12: 133-142.
31. Press Release: European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). London: European Medicines Agency 2009 19 February 2009. Doc. Ref. EMA/CHMP/20857/2009.
32. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008; 67 Suppl 3: 364-365.
33. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300: 1887-1896.
34. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
35. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritisand the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-2895.
36. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008; 9: 52.
37. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648-653.
38. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16: 254-261.
39. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006; 18: 129-134.
40. Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 334-339.
41. Widakowich C, de Castro G, Jr., de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007; 12: 1443-1455.
42. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-670.
43. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-1600.
44. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31: 459-467.
45. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795.
46. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007; 14: 1860-1869.
47. Klastersky J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol 2006; 18: 316-320.
48. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009; 69: 609-632.
49. Kuester K, Kloft C. In: Meibohm B Ed, Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Weinheim, WILEY-VCH. 2006; 45-91.
50. Strand V, Yazici Y. Interleukin-6 inhibition--tolerability profile and clinical implications. Bull NYU Hosp Jt Dis 2007; 65(Suppl 1): S21-S24.
51. Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H. Antiglobulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 1999; 68: 1417-1420.
52. Mukovozov I, Sabljic T, Hortelano G, Ofosu FA. Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thromb Haemost 2008; 99: 874-882.
53. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001; 39: 195-201.
54. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-2668.
55. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006; 24: 274-280.
56. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. London: European Medicines Agency 2007. Doc. Ref. EMA/CHMP/BMWP/14327/2006.
57. Gupta S, Indelicato SR, Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007; 321: 1-18.